NIDDM1
MCID: DBT093
MIFTS: 26

Diabetes Mellitus, Noninsulin-Dependent, 1 (NIDDM1)

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent, 1

MalaCards integrated aliases for Diabetes Mellitus, Noninsulin-Dependent, 1:

Name: Diabetes Mellitus, Noninsulin-Dependent, 1 57 29 40 72
Diabetes Mellitus, Noninsulin-Dependent 1 57 13
Niddm1 57 74
Diabetes Mellitus, Non-Insulin-Dependent, 1 74
Noninsulin-Dependent Diabetes Mellitus 1 57
Diabetes Mellitus, Non-Insulin-Dependent 72

Classifications:



External Ids:

OMIM 57 601283
MeSH 44 D003924
MedGen 42 C1832544
UMLS 72 C0011860 C1832544

Summaries for Diabetes Mellitus, Noninsulin-Dependent, 1

UniProtKB/Swiss-Prot : 74 Diabetes mellitus, non-insulin-dependent, 1: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, 1, also known as diabetes mellitus, noninsulin-dependent 1, is related to diabetes mellitus, noninsulin-dependent. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent, 1 is CAPN10 (Calpain 10). The drugs Metformin and Glimepiride have been mentioned in the context of this disorder. Affiliated tissues include kidney, eye and bone.

More information from OMIM: 601283

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent, 1

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent, 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 3 Diabetes Mellitus, Noninsulin-Dependent, 4
Diabetes Mellitus, Noninsulin-Dependent, 5

Diseases related to Diabetes Mellitus, Noninsulin-Dependent, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 10.5

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent, 1

Clinical features from OMIM:

601283

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent, 1

Drugs for Diabetes Mellitus, Noninsulin-Dependent, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Glimepiride Approved Phase 4 93479-97-1 3476
3
Glyburide Approved Phase 4 10238-21-8 3488
4
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
5
Zinc Approved, Investigational Phase 4 7440-66-6 32051
6
Saxagliptin Approved Phase 4 361442-04-8 11243969
7
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
10 Immunologic Factors Phase 4
11 Immunosuppressive Agents Phase 4
12 Anti-Arrhythmia Agents Phase 4
13 Hypoglycemic Agents Phase 4
14 Hormone Antagonists Phase 4
15 Sitagliptin Phosphate Phase 4
16 Hormones Phase 4
17 HIV Protease Inhibitors Phase 4
18 Dipeptidyl-Peptidase IV Inhibitors Phase 4
19 Incretins Phase 4
20
protease inhibitors Phase 4
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
22
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
23
Alogliptin Approved Phase 3 850649-61-5 11450633
24
Glucagon Approved Phase 2, Phase 3 16941-32-5
25
Insulin glargine Approved Phase 3 160337-95-1
26
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
27
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
28
Felodipine Approved, Investigational Phase 3 72509-76-3 3333
29
Fenofibrate Approved Phase 3 49562-28-9 3339
30
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
31
Simvastatin Approved Phase 3 79902-63-9 54454
32
tannic acid Approved Phase 3 1401-55-4
33
Triamterene Approved Phase 3 396-01-0 5546
34
Reserpine Approved, Investigational Phase 3 50-55-5 5770
35
Diltiazem Approved, Investigational Phase 3 42399-41-7 39186
36
Insulin Detemir Approved Phase 3 169148-63-4 5311023
37
Ramipril Approved Phase 3 87333-19-5 5362129
38
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
39
Repaglinide Approved, Investigational Phase 3 135062-02-1 65981
40
Angiotensin II Approved, Investigational Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
41
Lisinopril Approved, Investigational Phase 3 83915-83-7, 76547-98-3 5362119
42
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
43
Chlorthalidone Approved Phase 3 77-36-1 2732
44
Amlodipine Approved Phase 3 88150-42-9 2162
45
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
46
Terazosin Approved Phase 3 63590-64-7 5401
47
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
48
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
49
Benazepril Approved, Investigational Phase 3 86541-75-5 5362124
50
Hydralazine Approved Phase 3 86-54-4 3637

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 SCARF: Saxagliptin on CArdiac StRucture and Function Unknown status NCT02481479 Phase 4 Saxagliptin;Saxagliptin;saxagliptin
2 A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes Completed NCT00035568 Phase 4 Glucovance (metformin HCl/glyburide);or Metformin HCl alone;or Glyburide alone.
3 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin Completed NCT00329225 Phase 4 rosiglitazone
4 A Multicenter, Single Arm, Cohort Study to Evaluate the Efficacy and Safety of Saxagliptin 5mg, Once Daily for 24 Weeks, in Patients With Type 2 Diabetes Mellitus Completed NCT01608724 Phase 4 Saxagliptin
5 Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS Completed NCT01812122 Phase 4 Glimepiride;Vildagliptin
6 To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Completed NCT02299388 Phase 4 Liraglutide or Placebo
7 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
8 Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control Terminated NCT00832624 Phase 4 sitagliptin
9 A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy Completed NCT00044447 Phase 3 Glimepiride
10 Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus - Completed NCT00411554 Phase 3 sitagliptin phosphate;Comparator: voglibose
11 Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes Completed NCT01730534 Phase 3 Dapagliflozin 10 mg;Placebo tablet
12 A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. Completed NCT00035542 Phase 3 Glucovance (metformin HCl/glyburide);metformin HCl;glyburide
13 Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy Completed NCT00545584 Phase 3 sitagliptin phosphate
14 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT00701090 Phase 3 sitagliptin;Comparator: glimepiride;open-label metformin
15 A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin Completed NCT00875394 Phase 3 sitagliptin phosphate;Comparator: metformin;Comparator: metformin;Comparator: Antidiabetic Standard of Care
16 A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone Completed NCT00039026 Phase 3 AC2993;AC2993;Placebo;Placebo
17 A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea Completed NCT00035984 Phase 3 AC2993;AC2993;Placebo;Placebo
18 Diabetes Prevention Program Completed NCT00004992 Phase 3 Metformin;Placebo
19 A Phase III, Randomized, Placebo-controlled, Double-blind Clinical Trial and Subsequent Open-label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Voglibose Monotherapy Completed NCT00837577 Phase 3 Comparator: Placebo;Sitagliptin;Voglibose
20 A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes. Completed NCT00952991 Phase 3 LAF237 = vildagliptin
21 A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) Completed NCT00069784 Phase 3 insulin glargine (HOE901);omega-3 polyunsaturated fatty acids (PUFA);placebo
22 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Completed NCT01023581 Phase 3 Alogliptin;Metformin;Alogliptin Placebo;Metformin Placebo
23 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes Completed NCT00328627 Phase 3 Alogliptin;Alogliptin placebo;Pioglitazone;Pioglitazone placebo
24 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM Completed NCT02662400 Phase 2, Phase 3
25 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Completed NCT00000620 Phase 3 Anti-hyperglycemic Agents;Anti-hypertensive Agents;Blinded fenofibrate or placebo plus simvastatin
26 Does Zinc Supplementation Reduce the Extent of Oxidative Stress Damage in Diabetics? A Randomised Placebo-controlled Study. Completed NCT01309620 Phase 2, Phase 3
27 A Double-blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of BRL 49653C With Concurrent Sulphonylurea Therapy, When Administered to Patients With Non-insulin Dependent Diabetes Mellitus. Completed NCT01706211 Phase 3 BRL 49653C;Placebo
28 Phase II, Open-Label Study to Assess the Cardiovascular Side Effects and Efficacy for Reducing Blood Glucose Level in Type II Diabetes Mellitus Patients Being Treated With RAS 130 With or Without Diet and Exercise Unknown status NCT00737152 Phase 2
29 An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes Completed NCT00065312 Phase 2 naveglitazar
30 Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide Completed NCT00044707 Phase 2 Pramlintide acetate
31 Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects Completed NCT00758069 Phase 2 sitagliptin phosphate;Comparator: Placebo;Comparator: Sitagliptin
32 A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients Completed NCT00071422 Phase 2 INGAP-Peptide;INGAP-Peptide;placebo
33 Virtual World Health Behavior Counseling for Patients With Diabetes Completed NCT01340079 Phase 1, Phase 2
34 Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus Completed NCT02585505 Phase 1, Phase 2
35 A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Completed NCT00044694 Phase 2 Placebo 0.01 mL;Placebo 0.02 mL;Placebo 0.03 mL;Placebo 0.04 mL;AC2993 2.5 mcg;AC2993 5.0 mcg;AC2993 7.5 mcg;AC2993 10.0 mcg
36 A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus Completed NCT01007097 Phase 2 TAK-875;TAK-875;TAK-875;TAK-875;TAK-875;Glimepiride;Placebo
37 An Exploratory Study of the Effects of Oral Vitamin C Administration on Insulin Sensitivity and Vascular Reactivity in Subjects With Type 2 Diabetes Completed NCT00001870 Phase 2 Acetylcholine
38 Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
39 Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes Active, not recruiting NCT02801448 Phase 2 sulforaphane;Placebo
40 An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers Unknown status NCT02113163 Phase 1 Metformin Eicosapentaenoate;Metformin HCl and Vascepa
41 An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects Completed NCT00642798 Phase 1 sitagliptin phosphate
42 A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes Completed NCT00754130 Phase 1 Placebo;MK-0941
43 A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects Completed NCT00886821 Phase 1
44 Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects Completed NCT00979368 Phase 1 BMS-816336;BMS-816336;BMS-816336;BMS-816336;BMS-816336;Placebo
45 A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes Completed NCT00791661 Phase 1 MK-1006;Placebo
46 Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin Completed NCT01105429 Phase 1 BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;Placebo;Placebo
47 A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes Completed NCT00949091 Phase 1 TAK-875
48 A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus Completed NCT00957268 Phase 1 Alogliptin
49 NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes Completed NCT00013910 Phase 1 NNC 90-1170
50 The Efficacy of a Nurse-led Reminder Program on Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients. Unknown status NCT02196272

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent, 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acarbose
Acetohexamide
albiglutide
alogliptin
alogliptin benzoate
canagliflozin
Chlorpropamide
dulaglutide
empagliflozin
exenatide
glimepiride
Glipizide
Glyburide
Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin Glargine
insulin human, isophane
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Metformin
Metformin hydrochloride
miglitol
nateglinide
pioglitazone
Pioglitazone hydrochloride
Pramlintide
Regular Insulin, Human
repaglinide
rosiglitazone
Rosiglitazone maleate
sitagliptin
sitagliptin phosphate
Tolazamide
Tolbutamide
Tolbutamide sodium
troglitazone
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent, 1

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent, 1:

# Genetic test Affiliating Genes
1 Diabetes Mellitus, Noninsulin-Dependent, 1 29 CAPN10

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent, 1

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent, 1:

41
Kidney, Eye, Bone, Liver, Breast, Heart, Pancreatic Islet

Publications for Diabetes Mellitus, Noninsulin-Dependent, 1

Articles related to Diabetes Mellitus, Noninsulin-Dependent, 1:

(show all 29)
# Title Authors PMID Year
1
Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. 38 8
11017071 2000
2
Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. 38 8
9988276 1999
3
A large sample of finnish diabetic sib-pairs reveals no evidence for a non-insulin-dependent diabetes mellitus susceptibility locus at 2qter. 38 8
9710438 1998
4
A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. 38 8
8640221 1996
5
A novel 111/121 diplotype in the Calpain-10 gene is associated with type 2 diabetes. 8
16721485 2006
6
A genomewide search for type 2 diabetes-susceptibility genes in indigenous Australians. 8
11742441 2002
7
Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. 8
11673414 2001
8
Guilt by association. 8
11017062 2000
9
Association of calpain-10 polymorphisms with type 2 diabetes in the Tunisian population. 38
18487065 2008
10
Calpain-10 (NIDDM1) as a Susceptibility Gene for Common Type 2 Diabetes. 38
16873988 2006
11
Population genetics of CAPN10 and GPR35: implications for the evolution of type 2 diabetes variants. 38
15696418 2005
12
Linkage of calpain 10 to type 2 diabetes: the biological rationale. 38
14749261 2004
13
Meta-analysis of 4 coronary heart disease genome-wide linkage studies confirms a susceptibility locus on chromosome 3q. 38
12947017 2003
14
Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians. 38
12453914 2002
15
Perspective: the search for genes for type 2 diabetes in the post-genome era. 38
12021163 2002
16
[The UCSNP44 variation of calpain 10 gene on NIDDM1 locus and its impact on plasma glucose levels in type 2 diabetic patients]. 38
12133483 2002
17
Quantitative trait linkage analysis of lipid-related traits in familial type 2 diabetes: evidence for linkage of triglyceride levels to chromosome 19q. 38
11812765 2002
18
A statistical method for identification of polymorphisms that explain a linkage result. 38
11791210 2002
19
Role of calpain-10 gene variants in familial type 2 diabetes in Caucasians. 38
11836299 2002
20
Phenotyping of individual pancreatic islets locates genetic defects in stimulus secretion coupling to Niddm1i within the major diabetes locus in GK rats. 38
11723056 2001
21
[Diabetes mellitus]. 38
11307309 2001
22
A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. 38
11018080 2000
23
Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. 38
10958757 2000
24
Pathophysiological and genetic characterization of the major diabetes locus in GK rats. 38
10580437 1999
25
[Molecular biology and clinical diabetology]. 38
10199124 1999
26
Preliminary data on a genome search in NIDDM siblings: the NIDDM1 locus on chromosome 2 is not linked to NIDDM in the Sardinian population. Study Group for the Genetics of Diabetes in Sardinia. 38
9389433 1997
27
Mapping NIDDM susceptibility loci in French families: studies with markers in the region of NIDDM1 on chromosome 2q. 38
9200659 1997
28
Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. 38
8314023 1994
29
Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus. 38
1457761 1992

Variations for Diabetes Mellitus, Noninsulin-Dependent, 1

Expression for Diabetes Mellitus, Noninsulin-Dependent, 1

Search GEO for disease gene expression data for Diabetes Mellitus, Noninsulin-Dependent, 1.

Pathways for Diabetes Mellitus, Noninsulin-Dependent, 1

GO Terms for Diabetes Mellitus, Noninsulin-Dependent, 1

Sources for Diabetes Mellitus, Noninsulin-Dependent, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....